– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 –
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
Seeking Alpha / 1 hour ago 1 Views
Seeking Alpha / 1 hour ago 1 Views
– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 –
Comments